Information on the vaccines approved in Germany, the approved vaccine doses and the vaccine base composition for the 2020/2021 season
The basic composition of the influenza vaccines has to be adapted to the current epidemiological situation every year because the properties of the circulating influenza viruses change. The exact composition is determined each year by the World Health Organization (WHO). This adjustment is checked for each vaccine in a procedure to change the approval. After approval of the strain adaptation, the Paul-Ehrlich-Institut tests and releases the manufactured influenza vaccines in batches, which can then be put on the market and used.
Stand/ as of: 27.11.2020 (Quelle / Source: Paul-Ehrlich-Institut)
| Date | Calendar- week | Number of Doses of Vaccines (total Number) |
|---|---|---|
| 31.07.2020 | 31 | 801.010 |
| 07.08.2020 | 32 | aprox. 1.5 Million |
| 14.08.2020 | 33 | aprox. 2.6 Million |
| 21.08.2020 | 34 | aprox. 11.3 Million |
| 28.08.2020 | 35 | aprox. 13.6 Million |
| 04.09.2020 | 36 | aprox. 15.3 Million |
| 11.09.2020 | 37 | aprox. 16.5 Million |
| 18.09.2020 | 38 | aprox. 17.2 Million |
| 25.09.2020 | 39 | aprox. 18.1 Million |
| 02.10.2020 | 40 | aprox. 18.8 Million |
| 09.10.2020 | 41 | aprox. 19.1 Million |
| 16.10.2020 | 42 | aprox. 20.4 Million |
| 23.10.2020 | 43 | aprox. 22.3 Million |
| 30.10.2020 | 44 | aprox. 22.7 Million |
| 06.11.2020 | 45 | aprox. 23.1 Million |
| 13.11.2020 | 46 | aprox. 23.7 Million |
| 20.11.2020 | 47 | aprox. 24.0 Million |
| 27.11.2020 | 48 | aporx. 25.0 Million |
The influenza vaccine for the 2020/2021 season is composed of the antigens of globally circulating variants of viruses according to the recommendations of the WHO and the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA).
This composition differs from that of the 2019/2020 season.
| WHO Recommendations* for the northern hemisphere | Suitable strains according to the recommendations of the EMA |
|---|---|
| A/Guangdong-Maonan/SWL1536/2019 (H1N1) pdm09-like virus |
|
| A/Hong Kong/2671/2019 (H3N2)-like virus |
|
| B/Washington/02/2019 (B/Victoria/2/87 lineage)-like virus |
|
| B/Phuket/3073/2013 - like virus (B/Yamagata/16/88 lineage) |
|
| WHO Recommendations* for the northern hemisphere | Suitable strains according to the recommendations of the EMA |
|---|---|
| A/Hawaii/70/2019 (H1N1) pdm09-like virus | A/Nebraska/14/2019 (wild type) |
| A/Hong Kong/45/2019 (H3N2)-like virus | A/Delaware/39/2019 (wild type) |
| B/Washington/02/2019 (B/Victoria/2/87 lineage)-like virus | B/Darwin/7/2019 (wild type) |
| B/Phuket/3073/2013 - like virus (B/Yamagata/16/88 lineage) | B/Singapore/INFTT-16-0610/2016 (wild type) |
| WHO Recommendations* for the northern hemisphere | Suitable strains according to the recommendations of the EMA |
|---|---|
| A/Guangdong-Maonan/SWL1536/2019 (H1N1) pdm09-like virus | Virus MEDI 326775, derived from A/Hawaii/66/2019 |
| A/Hong Kong/2671/2019 (H3N2)-like virus | Virus MEDI 325078, derived from A/Hong Kong/2671/2019 |
| B/Washington/02/2019 (B/Victoria/2/87 lineage)-like virus | Virus MEDI 323797, derived from B/Washington/02/2019 |
| B/Phuket/3073/2013 - like virus (B/Yamagata/16/88 lineage) | Virus MEDI 306444, derived from B/Phuket/3073/2013 |
* A and B denote the virus types, the place name refers to the place of virus isolation; the first digit indicates the number of the isolated strain, the second refers to the year of isolation. H and N are the two most important proteins in the virus envelope hemagglutinin and neuraminidase, the number behind them indicates the current hemagglutinin and neuraminidase subtype.
Updated: 02.07.2021
